FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| Washington, D.C. 20549 | OMB APPROVAL | | | |
|--|--------------|------|--|--|
| STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP | OMB Number: | 3235 | | |

| OMB Number: | 3235-0287 | | | | | | | |
|--------------------------|-----------|--|--|--|--|--|--|--|
| Estimated average burden | | | | | | | | |
| hours per response: | 0.5 | | | | | | | |
| | | | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* Wang Theodore T | | | | | 2. Issuer Name and Ticker or Trading Symbol Bellerophon Therapeutics, Inc. [BLPH] | | | | | | | Relationship eck all appli X Directo | cable) | g Pers X | () | | |
|--|--|---------------------|--|-----------------|--|---|--------------|---------------------|-----------------------|--|---|---|---------------------------------|---|--------------------|--------|--|
| (Last) C/O PUI | ` | rst) APITAL MANA | (Middle) AGEMENT I | 100 | 3. Date of Earliest Transaction (Month/Day/Year) 06/05/2018 | | | | | | | Officer below) | (give title | | Other (s below) | pecify | |
| 950 THIRD AVENUE, 25TH FLOOR | | | | 4. | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | 6. Individual or Joint/Group Filing (Check Applicable | | | | | |
| (Street) | ORK N | Y | 10022 | | | | | | | Lin | Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | | |
| (City) | (Si | tate) | (Zip) | | | | | | | | | | | | | | |
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | | | | | | |
| Date | | | Transactio ate Month/Day/\ | Execution Date, | | Code (Instr. 5) | | | | Benefici | ies Feially (E Following (I) | | : Direct Indirect str. 4) | 7. Nature of Indirect Beneficial Ownership | | | |
| | | | Code V | | | Amount | (A) o (D) | Price | Transact (Instr. 3 | ction(s) | | | (Instr. 4) | | | | |
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | ive Conversion Date Execution Date, Transaction or Exercise (Month/Day/Year) if any Code (Instr. | | 5. Number of Expiration Date (Month/Day/Year) Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 6. Date Exercisable and of Securitie Underlying Derivative (Instr. 3 and Security 2) | | | ities Derivati ng Security ve Security (Instr. 5) | | | | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | | | | | | |
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | | | |
| Stock Option (right to buy) | \$2.27 | 06/05/2018 | | A | | 38,216 | | 06/05/2019 | 06/04/2028 | Common Stock | 38,216 | \$2.27 | 63,216 | 5 | D | | |

Explanation of Responses:

Remarks:

Theodore T. Wang

06/05/2018

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{*} If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).